ArticleLe Mali medical2025
[Value Of Bone Scintigraphy To Mdp-Tc 99m In The Management Of Prostate Cancer At The Institute Of Radioisotopes Of Niamey].
Article in Le Mali medical, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prostate cancer is a real public health problem. Studies have shown that 95% of deaths secondary to this cancer are due to metastases. The earlier metastases are diagnosed, the better the chances of survival. Objective: Analyze the results and show the contribution of bone scintigraphy in the management of prostate cancer in Niger. Methods: This was a retrospective descriptive and analytical study over a period of 8 years from February 09, 2014 to March 13, 2022 at the Department of Nuclear Medicine of the Institute of Radioisotopes of Niamey of patients who had undergone a bone scan as part of the management of prostate cancer. Results: The frequency of requesting bone scintigraphy concerning the prostate was 7%. The average age of our patients was 67.6 years with extremes ranging from 50 to 90 years. The most represented age group was 60 to 70 years. During the period of our study, bone scintigraphy was indicated in 93% of our patients as part of an initial assessment of prostate cancer. Urologists and oncologists were the main prescribers of this examination in 43.8% and 35.4% respectively. In our study, abnormal PSA > 20 ng/ml was predominant in 69.2%. Bone scintigraphy was abnormal in 72% (n=69) of cases. Bone lesions predominated on the axial + appendicular skeleton in 75.3% (n=52) with the most spinal injuries in 54%. Conclusion: Bone scintigraphy plays a diagnostic, therapeutic and prognostic role in prostatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.